SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-290820
Filing Date
2023-12-08
Accepted
2023-12-07 18:11:34
Documents
18
Period of Report
2023-12-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d627747d8k.htm   iXBRL 8-K 30598
2 EX-1.1 d627747dex11.htm EX-1.1 238509
3 EX-5.1 d627747dex51.htm EX-5.1 8979
4 EX-99.1 d627747dex991.htm EX-99.1 10234
5 EX-99.2 d627747dex992.htm EX-99.2 11962
9 GRAPHIC g627747g1208022117600.jpg GRAPHIC 2196
10 GRAPHIC g627747g1208022716001.jpg GRAPHIC 4091
  Complete submission text file 0001193125-23-290820.txt   510814

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA eypt-20231205.xsd EX-101.SCH 2859
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE eypt-20231205_lab.xml EX-101.LAB 17235
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eypt-20231205_pre.xml EX-101.PRE 10818
12 EXTRACTED XBRL INSTANCE DOCUMENT d627747d8k_htm.xml XML 3226
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 231473552
SIC: 3826 Laboratory Analytical Instruments